3 Ways to Review Your ISO 10993 Package Before Submission

Most deficiency findings in biological evaluation documentation are preventable. The issues that notified body reviewers flag are rarely obscure or borderline. They are missing sections, unsupported conclusions, and inconsistencies between documents that could have been caught with a thorough pre-submission review.

The question is not whether to review your package before submission. It is how. There are three general approaches, each with different strengths, and the right choice depends on your team, your device, and your timeline.

1. External expert review

Engaging a regulatory consultant or contract research organization is the traditional approach. Firms such as NAMSA, MCRA, Veranex, and specialized independent consultants offer gap analysis as a standalone service or as part of a broader biological evaluation engagement.

What it does well

A qualified external reviewer brings device-specific scientific judgment. They can evaluate whether your toxicological risk assessment is scientifically sound for your particular material and clinical application. They can assess whether your biological equivalence argument will hold up under scrutiny from a specific notified body. They bring pattern recognition from hundreds of prior submissions, which means they can identify weaknesses that are difficult to capture in any checklist.

For complex or high-risk devices, particularly Class III implants, devices involving novel materials, or long-term blood contact applications, an external expert's judgment is extremely important. These are the submissions where a scientific misjudgment in the documentation can result in months of delay.

Where it falls short

Cost is the most visible constraint. A standalone gap analysis engagement typically runs between $2,000 and $8,000 depending on scope and reviewer seniority.¹ Turnaround is typically two to four weeks. Availability can be an issue: the most experienced reviewers are often booked well in advance.

Consistency is a subtler limitation. The quality of a consultant-led review depends entirely on the individual performing it. Different reviewers within the same firm may focus on different areas, apply different standards of rigor, or produce reports in different formats. For teams managing a portfolio of devices, ensuring every package gets the same depth of review is challenging when the review is fully dependent on one person's bandwidth and attention on a given day.

2. Internal team review

Many companies conduct their pre-submission review internally, particularly those with experienced regulatory affairs teams. The RA lead or biocompatibility specialist reviews the documentation against the standard requirements and their own knowledge of regulatory expectations.

What it does well

Nobody knows your device better than your internal team. An in-house reviewer understands the materials, the manufacturing history, the clinical context, and every change that has been made over the device's lifecycle. They can evaluate the documentation in the context of the company's broader regulatory strategy, which an external reviewer may not fully grasp.

In-house review also carries no incremental cost beyond the reviewer's time, making it practical for routine updates, minor documentation revisions, or well-understood device families where the biological evaluation is largely unchanged between submission cycles.

Where it falls short

Familiarity bias is the first risk. The person who wrote the documentation, or who is closely familiar with it, is often the worst person to identify gaps. They know what the document is supposed to say, which makes it difficult to see what it actually says. Unsupported conclusions look supported when you know the underlying data exists somewhere, even if the document does not reference it.

Business pressure bias is the second risk, and it is rarely discussed openly. Internal reviewers do not operate in a vacuum. They work within organizations that have timelines, budgets, and commercial objectives. The pressure to minimize testing scope, reduce costs, and move submissions forward on schedule is real, and it can subtly influence how thoroughly an internal review is conducted. When the business needs a submission filed by end of quarter, the internal reviewer may not have the organizational standing to push back on documentation that is technically complete but substantively thin. An external reviewer or an independent evaluation tool does not face this pressure.

Bandwidth compounds the problem. At large medical device companies, a regulatory team may be managing 10 to 15 submission packages per year across a device portfolio. At smaller companies, the reviewer is often the same person who wrote the documentation, manages the submission timeline, and will respond to reviewer questions. In both cases, a thorough gap review requires focused time, and that time is the first thing compressed when deadlines tighten. The twelfth package of the year does not get the same attention as the second.

Calibration is the third concern. Even experienced in-house teams can fall out of step with evolving notified body expectations. Reviewers at major notified bodies see hundreds of biological evaluation packages per year. They develop expectations based on the strongest submissions they review, and those expectations shift over time. An internal team calibrated to the expectations of two years ago may miss gaps that current reviewers will not, particularly in areas where the 2025 revision of ISO 10993-1 has raised the bar.

3. Structured evaluation tool

A structured evaluation tool reads your biological evaluation documentation and assesses it against a defined set of requirements and quality criteria. This is the approach that BioEvalPro takes: the platform evaluates each section of your package, identifies gaps and unsupported claims, flags areas where statements conflict across documents, and provides specific guidance on how to strengthen the documentation.

What it does well

Consistency is the primary advantage. Every package gets evaluated against the same criteria, in the same depth, regardless of when it is submitted or how busy your week has been. This matters most for teams managing multiple devices or for consultants reviewing several client submissions in parallel.

Turnaround is measured in hours rather than weeks. For teams on tight timelines, receiving a structured gap report within 24 hours of uploading documentation can mean the difference between fixing issues before submission and discovering them in a deficiency letter months later.

Cost is significantly lower than a consultant engagement, which makes it practical to run the evaluation more than once: after the first draft to guide revisions, and again before final submission as a quality check. Running a consultant review twice on the same package is rarely economical. Running a tool-based evaluation twice is standard practice.

Cross-document consistency checking is another area where a structured tool adds particular value. One of the most common deficiency patterns is information that conflicts between the BEP, BER, chemical characterization section, and risk management file. These inconsistencies develop naturally when different sections are written at different times, sometimes by different authors. A systematic review that reads all sections and checks for conflicting statements catches issues that are easy for a human reviewer to miss, especially under time pressure.

Where it falls short

A structured evaluation tool cannot make device-specific scientific judgments. It can identify that your TRA does not cite tolerable exposure values, but it cannot determine whether the values you selected are the most appropriate for your clinical application. It can flag that your biological equivalence section does not address a specific dimension of comparison, but it cannot evaluate whether the comparator you selected is scientifically defensible.

This is by design. The tool evaluates documentation quality: whether claims are supported, whether required sections are present and complete, and whether the argumentation is internally consistent. The scientific and strategic judgment calls remain with your team or your contracted experts. For a detailed look at how this works in practice, see how BioEvalPro fits into your team's workflow.

Side-by-side comparison

	External Expert	Internal Team	Evaluation Tool
Cost per review	$2,000 to $8,000	Internal time only	Fraction of consultant cost
Turnaround	2 to 4 weeks	Depends on bandwidth	Within 24 hours
Review consistency	Varies by reviewer	Varies by bandwidth	Same criteria every time
Scientific judgment	Device-specific expertise	Device knowledge	Documentation quality focus
Familiarity bias	Low (external perspective)	High risk	None
Cross-document checks	Depends on engagement scope	Often limited by time	Systematic
Best suited for	Complex, high-risk devices	Routine updates	First-pass review, portfolios, tight timelines

When to use which approach

The most effective strategy for most teams is to combine two of these approaches rather than relying on one alone.

For high-risk or novel devices, engage an external expert for the scientific review and use a structured evaluation tool for the documentation quality check. Your consultant's time is better spent evaluating whether your TRA methodology is scientifically sound than checking whether your BEP addresses every required endpoint.

For routine updates or well-understood devices, an internal review paired with a tool-based evaluation is often sufficient. The tool catches the structural and consistency gaps that familiarity bias makes difficult to see internally.

For the 2018 to 2025 transition, run your existing documentation through BioEvalPro as a first pass to identify which 2025 requirements your current package does not address. This gives your team or consultant a prioritized list of gaps to start filling rather than working from a blank assessment. Then, once the updated documentation is drafted and approaching final form, run it through BioEvalPro again as a last-chance check before submission to confirm the identified gaps were actually addressed and no new inconsistencies were introduced during the revision process.

For consultants managing multiple clients, running every package through a structured evaluation before your expert review ensures consistent baseline quality across your portfolio, regardless of how many submissions you are handling that week.

If you are preparing a submission and want to see how your documentation holds up, request a gap analysis for early access to BioEvalPro, or get in touch to discuss how it fits into your review process.